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come countries. METHODS: We systematically reviewed the literature on the ap-
plication of CVD risk models in pharmacoeconomic studies. We assessed the qual-
ity of incorporation of risk models in these studies by evaluating the agreement of
the population characteristics and the time horizon applied between the risk
model and the pharmacoeconomic study, the appropriateness of the risk model for
the population studied, and the incorporation of the uncertainty of the risk model
in the sensitivity analysis. RESULTS: We identified 12 studies using published CVD
risk models. The studies demonstrated the usefulness of projecting intermediate
effectiveness endpoints to long term, health and cost related, benefits. However,
our quality assessment highlighted the distance between the populations of the
risk model and the studies reviewed, the disagreement between risk model and
study time horizons, and the lack of consideration of all uncertainty surrounding
risk predictions. CONCLUSIONS: Given that utilizing a risk model to project the
effect of a pharmacological intervention to CVD events provides an estimate of the
intervention’s clinical and economic impact, consideration should be paid on the
agreement between the study and risk model populations as well as the level of
uncertainty that these predictions add to the decision-analytic model. In the ab-
sence of hard endpoint trials, the value of risk models to model pharmacological
efficacy in primary CVD prevention remains high, although their limitation should
be acknowledged.
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OBJECTIVES: In developed countries mortality in the general population has been
declining for several decades and is anticipated to decrease further, especially
among the elderly. Life tables based on national statistics reflect mortality condi-
tions of a particular year and therefore do not take into account that survival
increases in the general population. As a consequence, life tables seem to system-
atically underestimate overall survival of the general population. Health economic
models use life tables to predict survival of the general population and may there-
fore also underestimate survival. Our study compares survival prediction methods
and discuss implications for health economic models. METHODS: Period life ex-
pectancy at age 50 calculated from Dutch mortality rates published for 2009 was
compared with life expectancy of a cohort aged 50 in 2009 calculated from pro-
jected mortality rates forecasted by the standard Lee-Carter approach. The Lee-
Carter model forecasts the level and age pattern of mortality based on the combi-
nation of singular value decomposition of mortality rates and statistical time series
methods. Mortality rates were taken from the Human Mortality Database. Projec-
tions were based on historical data between 1970 and 2009. RESULTS: Based on
projected mortality, cohort life expectancy was 34.97 years whereas period life
expectancy was only 32.37 years (2.60 years). When life years were discounted at
a 1.5% rate, the corresponding values were 25.31 and 26.40 years (1.09 years).
CONCLUSIONS: The analyses shows that taking into account the decrease in sur-
vival over time results in a difference of 7% in undiscounted and 4% in discounted
life expectancy in the Netherlands. This difference can have a substantial impact
on cost-effectiveness results, especially of curative interventions for diseases that
are life threatening or of prevention programmes over a long time horizon. In these
cases, sensitivity analysis should be carried out to investigate the impact of de-
creasing mortality.
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OBJECTIVES: The NICE reference case stipulates cost-utility analysis as the pre-
ferred form of economic evaluation, with health effects expressed in QALYs and
health states valued using a validated choice-based method such as the time-
trade-off (TTO). The evidence-base describing the impact of visual impairment (VI)
on quality-of-life is very limited. To date, the Czoski-Murray et al. (2009) utility
values for 4 visual health severity groups are considered the most plausible set of
utility values for use in eye-disorder economic models. These utility values, origi-
nally elicited through simulating VI similar to that associated with wet age-related
macular degeneration, were recently applied in other retinal disorders such as
diabetic macular edema. The objective of our analysis was to refine the mapping of
utilities onto visual acuity (VA). METHODS: OLS regression models were built to
estimate the relationship between mid-point VA of 4 visual health severity groups
and mean TTO scores as described in the literature. Linear and non-linear ap-
proaches for utility estimation as a function of the number of VA letters were
explored. RESULTS: The linear regression for utility estimation was found to be
statistically significant. The beta-coefficient for mid-point VA was 0.0054 (p0.030)
and 0.2864 for the constant term (p0.034). Linear regression estimates were used
to predict the utility value for 6 pre-specified VA health states: VA1 (0.766); VA2
(0.671); VA3 (0.616); VA4 (0.562); VA5 (0.507); VA6 (0.382). CONCLUSIONS: Published
evidence on utility values for deterministic visual health severity groups may not
easily transpose to alternative vision health-states. Our analysis demonstrated an
original approach for utility estimation allowing a more flexible and robust method
to map previously elicited VA-associated utilities onto alternate VA health-states.
This method allows wider applicability of VA-associated utility estimation in other
eye disorders characterized by VA impairment such as vitreomacular traction and
macular hole.
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OBJECTIVES: Dynamical processes in cost-effectiveness analysis (CEA) are typi-
cally described using Markov models that account for the full stochastic nature of
the process, or alternatively using systems of ordinary differential equations
(ODEs). In CEAs, ODEs are useful for defining dynamical systems with complex,
time-varying properties that often need to be considered, and are difficult to im-
plement as Markov models. However, in the field of CEA, fixed step sizes (‘cycle
lengths’) are used for solving systems of ODEs, which may result in bias if the step
size is too large in relation to the magnitude of change. The aim of this project was
to implement and demonstrate the use of a well established dynamical ODE solver
algorithm (LSODA) for CEAs in the statistical scripting language R, and to quantify
bias in outcome caused by use of a fixed-step size cohort simulation approach.
METHODS: To demonstrate the proposed approach, a previously reported CEA on
adjuvant breast cancer therapies was re-analysed using the ODE solver algorithm
LSODA. A model implementing the fixed-cycle length method was also developed
to compare bias by using a range of different cycle lengths. RESULTS: The CEA
model was successfully developed using the ODE solver LSODA. The use of fixed
cycle lengths resulted in bias compared to the outcome of the ODE model. A cycle
length of 1 year resulted in an underestimation of 0.016 absolute LYs (5.6%) and
€158 (6.8%) compared to the dynamical-step size model. CONCLUSIONS: The de-
veloped dynamical approach was found to be suitable for conduct of CEA’s and
flexible in use. Moreover, it was demonstrated that use of fixed cycle lengths could
potentially cause unnecessary bias in CEA outcomes. Finally, we advocate use of
scripting languages such as R in the field of health economics to improve transpar-
ency, reproducibility and overall integrity of conducted CEAs.
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OBJECTIVES: To compare cost-effectiveness model input influence on incremental
net monetary benefit (INMB) across three methods of uncertainty analysis: 1) one-
way sensitivity analysis; 2) probabilistic analysis of covariance (ANCOVA); and 3)
expected value of partial perfect information (EVPPI). METHODS: We replicated
and expanded a published HIV/AIDS cost-effectiveness Markov model (mono-
therapy vs. combination therapy) using TreeAge®. Case 1 assumed a willingness-
to-pay of £20,000/QALY (relatively low decision uncertainty in this application).
Case 2 assumed a willingness-to-pay of £8,000/QALY (relatively high decision un-
certainty). For Cases 1 and 2, one-way sensitivity analysis identified the ten most
influential inputs. From these ten inputs, we estimated ANCOVA results (10,000
Monte Carlo draws) and EVPPI for each input (1,000 inner and 1,000 outer draws).
For each case and method, we ranked inputs based on their influence on variation
of INMB and compared input ranks within case using Spearman’s rank correlation.
RESULTS:Mean INMB was £9,740 (Case 1) and £179 (Case 2) in favor of combination
therapy. Case 1: The two most influential inputs were the same across all uncer-
tainty methods, contributed 78% of variation in outcome (ANCOVA), and were the
only inputs with non-zero EVPPI values. Case 2: All inputs had non-zero EVPPI
values, with the two most influential inputs accounting for 49% of variation in
outcome (ANCOVA). For Cases 1 and 2, the influential input rank order correlations
across uncertainty methods ranged from 0.70 to 0.99 (all p-values  0.05 for pair-
wise uncertainty method correlations for both cases). CONCLUSIONS: For both
cases, the influential input ranks were positively correlated between one-way and
more advanced uncertainty analyses, indicating influential input rank agreement.
Although each method provides unique information, the additional resources
needed to generate and communicate advanced analyses should be weighed, es-
pecially when the outcome decision uncertainty and therefore value of informa-
tion is low. (i.e. Case 1).
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OBJECTIVES: In economic models that use Markov-type processes, it is generally
recommended that a ‘half-cycle correction’ be built into the analysis, to account for
the fact that events can occur at any point during the cycle. This study explores the
implications of the half-cycle correction, and highlights a number of flaws in the
approach. METHODS: A brief review of health technology assessment models was
undertaken to determine the use of half-cycle corrections. The study aimed to
explore the theoretical, practical and mathematical implications of the half-cycle
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